Related Experiment Videos
Endothelin in myocardial ischaemia and reperfusion
Insights
Endothelin-1 (ET-1) plays a role in heart injury after ischemia and reperfusion. Blocking ET-1 actions reduced injury in animal models, but results vary, possibly due to study differences.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Pathophysiology
Background:
- Endothelin-1 (ET-1), a potent vasoconstrictor, is produced by endothelial cells, smooth muscle cells, and cardiomyocytes.
- Elevated ET-1 plasma levels are observed in cardiovascular disorders like atherosclerosis, myocardial infarction, and heart failure.
- Myocardial ET-1 production and coronary constrictor response increase during ischemia/reperfusion, suggesting a role in injury.
Purpose of the Study:
- To investigate the pathophysiological role of ET-1 in myocardial ischemia/reperfusion (I/R) injury.
- To evaluate the cardioprotective effects of pharmacological blockade of ET-1 actions in experimental I/R injury models.
Main Methods:
- Utilized various pharmacological tools including monoclonal antibodies, ET converting enzyme inhibitors, and ET receptor antagonists.
- Assessed the impact of ET-1 blockade on infarct size, myocardial performance recovery, and coronary flow in experimental animal models of I/R injury.
Main Results:
- Pharmacological inhibition of ET-1 actions reduced myocardial I/R injury in animal models.
- Observed reductions in infarct size and improvements in myocardial performance and coronary flow.
- Noted conflicting results in some studies regarding the cardioprotective effects of ET receptor antagonists.
Conclusions:
- ET-1 blockade demonstrates potential cardioprotective effects against myocardial I/R injury.
- Discrepancies in study outcomes may stem from variations in animal species, drug administration, and experimental protocols.
- Potential mechanisms for cardioprotection include prevention of no-reflow, reduced neutrophil activation, and direct effects on myocytes.
Abstract:
Endothelin-1 (ET-1) is an extremely potent vasoconstrictor peptide derived from vascular endothelial cells. ET-1 can also be produced by other cell types such as smooth muscle cells and cardiomyocytes. Plasma levels of ET-1 are elevated during several different cardiovascular disorders like atherosclerosis, myocardial infarction and congestive heart failure. During and following myocardial ischaemia and reperfusion, the myocardial production and release of ET-1 is stimulated and the coronary constrictor response to ET-1 is enhanced. These findings all favour a pathophysiological role for ET-1 in the development of ischaemia/reperfusion injury. Accordingly, by using different pharmacological tools (monoclonal antibody, ET converting enzyme inhibitor or ET receptor antagonists) that block the biological actions of ET-1, myocardial ischaemia/reperfusion injury has been demonstrated to be reduced in experimental animal models, in terms of both reduction in final infarct size and improved recovery of myocardial performance and coronary flow. However, some studies have shown no cardioprotective effects of ET receptor antagonists. Possible explanations for these apparently conflicting results are differences in animal species used, route and timing of drug administration, experimental protocol and chemical nature of the antagonists. The potential mechanisms underlying the cardioprotective effects of ET antagonists are discussed and include prevention of no-reflow, inhibition of ET-induced neutrophil activation, abolishment of direct pro-ischaemic actions of ET on myocytes, and interruption of interference of ET with the renin-angiotensin system.